In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...

Patients on prasugrel therapy have greater platelet inhibition than those taking maintenance doses of clopidogrel and thus require a longer time to return to baseline reactivity after stopping the ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

Barcelona, Spain, 31 August: Studies from a growing body of convincing data show that responsiveness to antiplatelet therapy is real. This is a clinically important issue and there is a need to ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Platelets are small types of blood cells that prevent excessive bleeding. It’s possible to develop low or high platelet counts related to a number of health conditions. Platelets are one of the main ...

February 2, 2007 (Jacksonville, FL) - A 150-mg maintenance dose of clopidogrel may be more appropriate than the standard 75-mg dose for patients with type 2 diabetes who are at higher risk of ...